B+
Bull case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
WVE
Wave Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$2.90
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-26
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+51.3
Score
AI commentary
Recent company announcements provide concrete trial, regulatory-pathway and collaboration milestones, but the $3.18 October 23 anchor shows no established post-announcement reaction or cause. The October 27 results and November 4 Research Day are still ahead. Independent analyst revisions, a usable target distribution, options skew, short interest and sufficiently covered social sentiment are unavailable; zero-valued sentiment fields denote unavailable data, not neutral observations. The stored earnings document concerns GSK rather than WVE and is excluded. Wave press releases
RankAlpha Sentiment Codex - 2026-10-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-27eventThird-quarter cash and program updateMedium impact
Wave scheduled third-quarter results and a business update for October 27. The decision-relevant checks are cash runway and progress toward the WVE-006 and WVE-007 milestones; the July results release reported $490.6 million in cash, cash equivalents and marketable securities at June 30 and an expected runway into the third quarter of 2028. [#SEC-8K-2026-07-30] Wave results announcement
2026-11-04eventResearch Day platform and WVE-008 evidenceMedium impact
Wave scheduled November 4 Research Day to present new platform data, including RNA editing and hepatic capabilities, plus discussion of PNPLA3 liver disease. Assess whether the evidence advances WVE-008 beyond a platform narrative; no clinical efficacy readout was promised in the announcement. [#PR-2026-10-19] Wave Research Day announcement
2026-12-31eventWVE-006 monthly-dose clinical dataHigh impact
Wave expects fourth-quarter 2026 data from the 600 mg monthly multidose RestorAATion-2 cohort. Biomarker durability and safety will test the case for its planned AATD registrational trial. Wave reports FDA alignment on key aspects of that plan, not approval. [#PR-2026-10-01] Wave FDA update
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-26 • Updated nightlySource: Internal modelMethodology